WuXi AppTec (2359.HK): Continuation of the Uptrend

WuXi AppTec (2359), a pharmaceutical company, jumped 7% yesterday as investors chased the technology stock after Nasdaq marked a new record high. After the outbreak of coronavirus, health technology is one of the strongest sectors in the Hong Kong Market.

Uptrend 1

WuXi AppTec (2359), a pharmaceutical company, jumped 7% yesterday as investors chased the technology stock after Nasdaq marked a new record high. After the outbreak of coronavirus, health technology is one of the strongest sectors in the Hong Kong Market.

The company soared around 85% from March low, while the Hang Seng Index was only up 18%. The performance of the company is outperforming.

Recently, the company reported that 2Q adjusted net income jumped 43.1% on year to 942 million yuan on operating revenue of 4.04 billion yuan, up 29.4%.

Besides, the company was rated "new buy" at Jefferies with target prices at HK$145.

From a technical point of view, the stock is supported by a rising trend line drawn from May on a daily chart. In addition, the RSI is also riding above the bullish trend line drawn from March. In addition, the prices have recorded a series of higher tops and higher bottoms since March low.

Bullish readers could consider placing the nearest support level at HK$104, while the resistance levels would be located at HK$130.2 (100% measured move) and HK$136.7 (127.2% measured move).


Source: GAIN Capital, TradingView

Join our live webinars for the latest analysis and trading ideas. Register now

GAIN Capital UK Limited (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.